Hundreds of Drug Prices Rise Again Despite Pressure From Trump

What Happened 

U.S. pharmaceutical companies moved forward with price increases on more than 350 branded medicines at the start of the year, according to data provided by healthcare research firm 3 Axis Advisors. The increases came despite sustained pressure from the Trump administration to curb drug costs and public scrutiny over affordability.

The hikes affect a wide range of commonly used treatments. Among the drugs with higher list prices are Pfizer’s breast cancer medication Ibrance, the migraine drug Nurtec, and several COVID-19, RSV, and shingles vaccines. Other increases apply to medicines used to treat chronic conditions, including autoimmune disorders and cardiovascular disease.

Most of the price hikes are relatively modest on paper, with a median increase of around 4%. Still, when applied across hundreds of drugs and sustained over time, those increases can significantly raise costs for patients, insurers, and government programs.

A smaller group of medications will see price reductions, largely tied to Medicare negotiated pricing under existing federal rules. One example is the diabetes drug Jardiance, which is expected to receive a lower price for Medicare beneficiaries. Those reductions, however, apply to a narrow slice of the market and do little to offset the wider upward trend.

Why It Matters 

List price increases do not always translate directly into higher out-of-pocket costs, but they shape the entire pricing system. Higher list prices influence insurance premiums, employer health plans, and government spending, even when rebates and negotiations reduce what some patients ultimately pay.

The timing is notable. Drugmakers are raising prices while publicly arguing that costs are needed to fund research, development, and future innovation. At the same time, policymakers across parties continue to point to high drug prices as a core driver of healthcare costs and voter frustration.

The increase emphasizes how limited political pressure has been on its own. Public warnings and targeted Medicare negotiations have narrowed prices in a few areas, but manufacturers still have relatively free rein to raise costs across most of the market. The gap between stated goals and actual outcomes is becoming harder to ignore.

For an industry already under close scrutiny, repeated price hikes risk deepening public skepticism. Each increase reinforces the sense that the system continues to reward higher prices, regardless of political messaging or reform efforts.

How It Affects Readers 

For patients, the effects tend to surface slowly rather than all at once. Higher list prices feed into insurance premiums, deductibles, and cost sharing over time, quietly raising what people pay each year. Even when prescriptions at the pharmacy counter do not immediately cost more, long-term affordability often slips as overall coverage becomes more expensive.

Employers and insurers shoulder part of the increase, but those costs rarely disappear. They influence plan design, coverage limits, and benefit decisions, and often flow back to workers through higher employee contributions or slower wage growth.

For policymakers, the latest price hikes sharpen an already difficult debate. Negotiated price reductions can lower costs for select drugs and groups, but the pricing system as a whole still allows manufacturers plenty of room to raise prices across the market.

Taken together, the increases reflect a deeper challenge within the U.S. healthcare system. Without more fundamental changes, public pressure alone is unlikely to reverse long-term pricing trends. Patients remain caught between promises of reform and an industry that continues to raise prices.